United Therapeutics Corporation (BMV:UTHR)
Mexico · Delayed Price · Currency is MXN | Market Cap | 389.41B +53.1% |
| Revenue (ttm) | 55.12B +2.5% |
| Net Income | 22.91B +5.5% |
| EPS | 488.35 +9.0% |
| Shares Out | n/a |
| PE Ratio | 17.00 |
| Forward PE | 17.04 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12 |
| Open | 9,680.00 |
| Previous Close | 9,535.62 |
| Day's Range | 9,680.00 - 9,680.00 |
| 52-Week Range | 5,672.39 - 9,884.33 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About United Therapeutics
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of tre... [Read more]
Financial Performance
In 2025, United Therapeutics's revenue was $3.18 billion, an increase of 10.61% compared to the previous year's $2.88 billion. Earnings were $1.33 billion, an increase of 11.68%.
Financial numbers in USD Financial StatementsNews
United Therapeutics price target lowered to $515 from $516 at Morgan Stanley
Morgan Stanley analyst Terence Flynn lowered the firm’s price target on United Therapeutics (UTHR) to $515 from $516 and keeps an Equal Weight rating on the shares after the company…
United Therapeutics price target lowered to $677 from $704 at RBC Capital
RBC Capital lowered the firm’s price target on United Therapeutics (UTHR) to $677 from $704 and keeps an Outperform rating on the shares. United Therapeutics reported Tyvaso weakness with another…
United Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 revenue was $783M, flat sequentially, with TYVASO pressured by competition but DPI showing growth. Major clinical milestones and regulatory filings position for multi-billion-dollar opportunities in PAH and IPF, with stronger performance expected in H2 2026.
United Therapeutics Quarterly report: Q2 2026
United Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
United Therapeutics Slides: Q2 2026
United Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
United Therapeutics Earnings release: Q2 2026
United Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
United Therapeutics reports Q2 EPS $7.27, consensus $6.86
Reports Q2 revenue $783.3M, consensus $804.65M. “We just submitted what we believe are two of the most important NDAs in rare pulmonary disease history: ralinepag tablets in PAH and Nebulized…
United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ...
United announces publication from Advance Outcome study in The Lancet
United Therapeutics (UTHR) announced that The Lancet has published full results of its ADVANCE OUTCOMES study. Ralinepag has not been approved for use in any indication by the FDA and…
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that The Lancet has published full res...
United Therapeutics price target raised to $687 from $685 at JPMorgan
JPMorgan raised the firm’s price target on United Therapeutics (UTHR) to $687 from $685 and keeps an Overweight rating on the shares.
United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors
SILVER SPRING, Md. & DURHAM, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors appointed Victor...
United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2026 financial results in a pr...
United Therapeutics price target lowered to $613 from $620 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on United Therapeutics (UTHR) to $613 from $620 and keeps a Neutral rating on the shares. Second quarter results are expected…
United Therapeutics acquires Thymmune Therapeutics
United Therapeutics (UTHR) has acquired Thymmune Therapeutics, a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treat...
United Therapeutics Corporation Acquires Thymmune Therapeutics
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately h...
FDA premarket approval of LungFX positive for United Therapeutics, says Leerink
Leerink views the FDA’s premarket approval of LungFX as “an incremental positive” for United Therapeutics (UTHR) and the transplantation space overall, the analyst tells investors. The approval repres...
United Therapeutics announces FDA approval of the LungFX device
United Therapeutics (UTHR) announced that the U.S. FDA has granted premarket approval of the LungFX device for use in centralized ex vivo lung perfusion, a procedure that enables donor lungs…
United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administra...
United Therapeutics Transcript: AGM 2026
The virtual annual meeting marked the company's 30th anniversary, with all director nominees elected and all shareholder proposals approved. No questions were raised by shareholders, and voting results will be reported in a forthcoming SEC filing.
The space race is coming for pharma: Why drug development is heading to lower Earth orbit
Industries from semiconductors to fiber-optic cables stand to benefit from space research and manufacturing, but experts told CNBC that medicine could see the most immediate disruption. A flurry of co...
United Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Multiple late-stage clinical successes in IPF and PAH are driving confidence in achieving a $1 billion quarterly run rate by 2027, with further revenue growth expected from new indications and product launches. Expansion of the sales force and ongoing pivotal trials in PPF and xenotransplantation support a robust long-term outlook.
United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will prov...
United Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
Significant clinical progress in IPF and PAH is expected to drive revenue growth, with TYVASO and ralinepag positioned for major label expansions. Regulatory filings and new product launches are on track, while organ manufacturing programs advance toward addressing unmet needs.